Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)

Julia Huetter, Uwe Gritzan, Ilona Gutcher, Wolf-Dietrich Doecke, Merlin V. Luetke-Eversloh, Sven Golfier, Helge G. Roider, Anna-Lena Frisk, John Hunter, Andrew Pow, Andrew Drake, Zurit Levine, Ofer Levy, Meir Azulay, Inbal Barbiro, Gady Cojocaru, Ilan Vaknin, Bertolt Kreft and Lars Roese
Julia Huetter
1Immuno-Oncology (Research), Pharmaceuticals Division, Bayer AG, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Gritzan
2Global Biologics, Pharmaceuticals Division, Bayer AG, Cologne, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilona Gutcher
1Immuno-Oncology (Research), Pharmaceuticals Division, Bayer AG, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolf-Dietrich Doecke
3Biomarker Strategy, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merlin V. Luetke-Eversloh
4Biomarker Research, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven Golfier
4Biomarker Research, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helge G. Roider
5Bioinformatics, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Lena Frisk
1Immuno-Oncology (Research), Pharmaceuticals Division, Bayer AG, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Hunter
6Compugen USA Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Pow
7New Paradigm Biosciences, Woburn, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Drake
6Compugen USA Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zurit Levine
8Compugen Ltd., Holon, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ofer Levy
8Compugen Ltd., Holon, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meir Azulay
8Compugen Ltd., Holon, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inbal Barbiro
8Compugen Ltd., Holon, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gady Cojocaru
8Compugen Ltd., Holon, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilan Vaknin
8Compugen Ltd., Holon, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bertolt Kreft
1Immuno-Oncology (Research), Pharmaceuticals Division, Bayer AG, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Roese
1Immuno-Oncology (Research), Pharmaceuticals Division, Bayer AG, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lars.roese@bayer.com
DOI: 10.1158/2326-6066.CIR-19-0321 Published July 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: April 2020 to March 2021

AbstractFull-text HTMLPDF
Total179814131230

Cited By

Article Information

Volume 8, Issue 7, pp. 895-911

DOI 
https://doi.org/10.1158/2326-6066.CIR-19-0321
PubMed 
32312711

Published By 
American Association for Cancer Research
Print ISSN 
2326-6066
Online ISSN 
2326-6074
History 
  • Received May 8, 2019
  • Revision received November 15, 2019
  • Accepted April 13, 2020
  • Published first April 20, 2020.

Article Versions

  • Previous version (April 20, 2020 - 00:00).
  • Previous version (May 27, 2020 - 05:36).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2020 American Association for Cancer Research.

Author Information

  1. Julia Huetter1,
  2. Uwe Gritzan2,
  3. Ilona Gutcher1,
  4. Wolf-Dietrich Doecke3,
  5. Merlin V. Luetke-Eversloh4,
  6. Sven Golfier4,
  7. Helge G. Roider5,
  8. Anna-Lena Frisk1,
  9. John Hunter6,
  10. Andrew Pow7,
  11. Andrew Drake6,
  12. Zurit Levine8,
  13. Ofer Levy8,
  14. Meir Azulay8,
  15. Inbal Barbiro8,
  16. Gady Cojocaru8,
  17. Ilan Vaknin8,
  18. Bertolt Kreft1, and
  19. Lars Roese1,*
  1. 1Immuno-Oncology (Research), Pharmaceuticals Division, Bayer AG, Germany.
  2. 2Global Biologics, Pharmaceuticals Division, Bayer AG, Cologne, Germany.
  3. 3Biomarker Strategy, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
  4. 4Biomarker Research, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
  5. 5Bioinformatics, Pharmaceuticals Division, Bayer AG, Berlin, Germany.
  6. 6Compugen USA Inc., South San Francisco, California.
  7. 7New Paradigm Biosciences, Woburn, Massachusetts.
  8. 8Compugen Ltd., Holon, Israel.
  1. ↵*Corresponding Author:
    Lars Roese, Bayer AG, Muellerstr 178, Berlin 13353, Germany. Phone: 4930-4681-93096, E-mail: lars.roese{at}bayer.com
View Full Text
PreviousNext
Back to top
Cancer Immunology Research: 8 (7)
July 2020
Volume 8, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
Julia Huetter, Uwe Gritzan, Ilona Gutcher, Wolf-Dietrich Doecke, Merlin V. Luetke-Eversloh, Sven Golfier, Helge G. Roider, Anna-Lena Frisk, John Hunter, Andrew Pow, Andrew Drake, Zurit Levine, Ofer Levy, Meir Azulay, Inbal Barbiro, Gady Cojocaru, Ilan Vaknin, Bertolt Kreft and Lars Roese
Cancer Immunol Res July 1 2020 (8) (7) 895-911; DOI: 10.1158/2326-6066.CIR-19-0321

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
Julia Huetter, Uwe Gritzan, Ilona Gutcher, Wolf-Dietrich Doecke, Merlin V. Luetke-Eversloh, Sven Golfier, Helge G. Roider, Anna-Lena Frisk, John Hunter, Andrew Pow, Andrew Drake, Zurit Levine, Ofer Levy, Meir Azulay, Inbal Barbiro, Gady Cojocaru, Ilan Vaknin, Bertolt Kreft and Lars Roese
Cancer Immunol Res July 1 2020 (8) (7) 895-911; DOI: 10.1158/2326-6066.CIR-19-0321
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • TGF Influences Alternative Splicing of Irf1 in Th1 Cells
  • Machine Learning–Based Prognostic Marker of HCC
  • Lenalidomide Turns Myeloma-Associated Macrophage Tumoricidal
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement